Navigation Links
QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Date:8/22/2007

need for women and for physicians seeking alternatives to hormone therapies."

Dr. Alan Altman, Assistant Clinical Professor of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School and an expert on menopause, commented "Physicians are now seeing an epidemic of vaginal symptoms, such as dryness, irritation and sexual pain, in post-menopausal patients as a result of large numbers of women stopping hormone treatment due to fear instilled by what they have read about the Women's Health Initiative Study. Chronic symptoms such as these have a major adverse impact on quality of life for these women and highlight the need for new treatment options in those wanting to avoid estrogen use."

About Postmenopausal Vaginal Syndrome

Postmenopausal Vaginal Syndrome (PVS) is a chronic condition characterized by vaginal symptoms including dryness, sexual pain (dyspareunia), and irritation. Declining estrogen levels during menopause may cause tissues of the vaginal lining to grow thinner and to lose elasticity, a condition known as atrophy. Dryness and irritation associated with decreases in vaginal secretions often cause pain or bleeding during sexual intercourse. The decline in estrogen also contributes to an increase in vaginal pH, creating an environment more susceptible to infection. There are more than 64 million women in the United States who are over 40 years old. It is estimated that up to 40% of post-menopausal women will have symptoms of PVS. Current treatments approved for this condition all contain estrogen, administered either orally or locally in the vagina. Other currently available SERMs do not have an effect on vaginal tissue and may induce hot flashes.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has three other product candidates in active cl
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Monitoring Patient Glucose Levels: New Advances in software make it easier
6. Managing Preanalytical Processes for Patient Safety
7. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
8. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... PHOENIX , Sept. 22, 2014  For ... wrists, surgery often means facing the prospect of ... can be imagined, regular activities are also impacted, ... on the severity of the problem, some patients ... braces, which can even lead to permanent damage ...
(Date:9/22/2014)... Sept. 22, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... initiated a phase I clinical trial in patients ... safety, tolerability, and immunogenicity of INO-3106. This immunotherapy ... most aerodigestive cancers. Aerodigestive cancers affect ... and parts of the esophagus and windpipe. The ...
(Date:9/22/2014)... , Sept. 22, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... pleased to announce that TUV-SUD and The Medicinal ... (MEB) has granted its request for a ... Neutrolin was initially approved in July 2013 for ...
Breaking Medicine Technology:Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3
(Date:9/22/2014)... UK (PRWEB) September 22, 2014 The ... in the recent years. The statistically important data received ... safety of cancer vaccines. The primary challenge to the ... information about the exact mechanism of how a human’s ... to various results in different individuals owing to known ...
(Date:9/22/2014)... New York, New York (PRWEB) September 22, 2014 ... risks associated with the use of power morcellators ... Liebhard LLP notes a new report detailing the ... despite warnings from federal regulators that specifically discouraged ... these physicians believe that the potential cancer risks ...
(Date:9/22/2014)... 2014 (HealthDay News) -- Two new prescription devices approved ... provide some relief for people with migraine headaches who ... study. One device -- the Cefaly -- is ... the Cerena -- is meant to be used when ... "Patients have been looking for alternative migraine treatments. ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... a new AS365 N3+ Dauphin, the latest version of ... which is based at Miami Valley Hospital ... air medical transport helicopters. , “We have a lot ... Health Vice President, Emergency, Trauma, and CareFlight. “We’ve been ...
(Date:9/22/2014)... In a continued effort to support the ... launching an awareness campaign inspired by the ice bucket ... to raise awareness and funds for the cause. , ... the air and trying to catch it while blindfolded. ... nominee does not complete the challenge within 24 hours ...
Breaking Medicine News(10 mins):Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2
... SETO Holdings, Inc. (Pink Sheets: SETO) announced that it signed ... (1) to issue shares of its Common Stock to acquire ... ("AHC"), a Maryland corporation which provides hearing services and retails ... Virginia, and (2) to sell all of SETO,s current businesses, ...
... how that happens may lead to ways around it, ... Temozolomide, a standard treatment for brain cancer, may boost ... more likely, a new study suggests. , The research ... City, have identified cells in brain tumors called gliomas ...
... Company Records 172% Year over Year Revenue Growth and ... Insulet,s International ExpansionBrian Roberts Appointed CFOBEDFORD, Mass., March 5 ... leader in tubing-free insulin pump technology with its OmniPod(R) ... fourth quarter and full year ended December 31, 2008. ...
... SEATTLE, March 5 Trubion Pharmaceuticals Inc. (Nasdaq: ... issue earnings results for the fourth quarter and year ... on March 12, 2009. The company,s earnings conference call ... Pacific Time, 5 p.m. Eastern Time. Both live events ...
... editors of the Harvard Health Letter , in consultation with the ... health care spending, saving society--and perhaps yourself--some money , ... Boston, MA ... will falter unless health care spending is brought under control. Moreover, even ...
... OpportunitiesHARRISBURG, Pa., March 5 Insurance Commissioner ... off from a job that offered health insurance to ... them with relief on premiums and that now is ... want to let Pennsylvanians know that additional help in ...
Cached Medicine News:Health News:SETO Holdings, Inc. Signs Letter of Intent to Dispose of all its Existing Businesses and Acquire Advanced Hearing Centers, Inc.; New Management to be Installed. 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 3Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 2Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 3Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 4Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 5Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 6Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 7Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 8Health News:Trubion Announces Dates for Fourth-Quarter and Year-Ended 2008 Earnings Conference Call 2Health News:Runaway Health Care Costs: 12 Ways You Can Rein Them in, from the Harvard Health Letter 2Health News:Runaway Health Care Costs: 12 Ways You Can Rein Them in, from the Harvard Health Letter 3Health News:Pennsylvanians Encouraged to Take Another Look at COBRA Options 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: